Cellenkos® selects cryoport to support on-demand, flexible covid-19 therapy shipments to patients in need

Nashville, tenn., june 22, 2021 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) ("cryoport" or "the company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that cellenkos ® , inc., a privately held, clinical-stage biotechnology company, has selected cryoport to provide a staged, on-demand, logistics solution for covid-19 therapy shipments for patients in need.
CYRX Ratings Summary
CYRX Quant Ranking